Alerts will be sent to your verified email
Verify Email
SUVEN
|
Suven Life Sciences
|
Hikal
|
Piramal Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
R&D as a % of Total Sales
|
1683.57 % | 4.01 % | 0.14 % |
|
Financials
|
|||
|
5 yr Average ROE
|
-82.05 % | 10.48 % | 3.82 % |
|
5yr average Equity Multiplier
|
1.55 | 2.17 | 1.94 |
|
5yr Average Asset Turnover Ratio
|
0.05 | 0.81 | 0.55 |
|
5yr Avg Net Profit Margin
|
-1150.51 % | 5.87 % | 3.51 % |
|
Price to Book
|
55.09 | 3.1 | 3.12 |
|
P/E
|
0.0 | 43.07 | 258.34 |
|
5yr Avg Cash Conversion Cycle
|
97.84 Days | 33.87 Days | -19.3 Days |
|
Inventory Days
|
10.88 Days | 64.21 Days | 70.13 Days |
|
Days Receivable
|
71.91 Days | 101.46 Days | 77.05 Days |
|
Days Payable
|
3.38 Days | 96.57 Days | 159.9 Days |
|
5yr Average Interest Coverage Ratio
|
-373.47 | 4.8 | 2.86 |
|
5yr Avg ROCE
|
-82.34 % | 13.73 % | 6.75 % |
|
5yr Avg Operating Profit Margin
|
-1227.3 % | 16.42 % | 15.15 % |
|
5 yr average Debt to Equity
|
0.0 | 0.68 | 0.62 |
|
5yr CAGR Net Profit
|
17.38 % | -3.79 % | -35.79 % |
|
5yr Average Return on Assets
|
-54.63 % | 4.82 % | 2.03 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
70.27 % | 68.85 % | 34.86 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
5.29 % | 0.08 % | 0.07 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 2.2 % | 11.78 % |
|
Suven Life Sciences
|
Hikal
|
Piramal Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|